The U.S. Food and Drug Administration has reversed an earlier decision and said it will review drugmaker Moderna's application for approval of a seasonal flu vaccine, the company said in a statement W...

The FDA says it will now review a new m-r-n-a flu vaccine from Moderna.

The FDA news is largely positive for MRNA stock as it positions the company’s influenza vaccine for the upcoming flu season.